title: Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1.
abstract: Cell surface heparan sulfate proteoglycans (HSPGs) are involved in the binding and entry of human T-cell leukemia virus type 1 (HTLV-1) into host cells, while sulfated polysaccharides such as heparin inhibit HTLV-1 infection. Chondroitin sulfate proteoglycans (CSPGs) are classified as another major type of proteoglycans. Here, we examined the effect of four types of chondroitin sulfate (CS) on HTLV-1 infection. Accordingly, a human T cell line, MOLT-4, was inoculated with cell-free HTLV-1 in the presence or absence of soluble CS, and the synthesis of reverse-transcribed HTLV-1 DNA within cells 20 h after inoculation was detected using polymerase chain reaction (PCR). Among the four types of CS (A, C, D, and E), the E type (CSE), which was derived from the squid cartilage, exhibited anti-HTLV-1 activity. Furthermore, we observed that CSE directly interacted with recombinant HTLV-1 envelope (Env) proteins and inhibited the binding of HTLV-1 virions to MOLT-4 cells, indicating that the interaction between Env and CSE plays a significant role in its anti-HTLV-1 activity. In addition, CSE inhibited syncytium formation that was induced by HTLV-1-producing cells. When CSE was mixed with the synthetic fusion inhibitor peptide corresponding to the ectodomain of the Env transmembrane subunit (TM) gp21, the HTLV-1 infection was further inhibited when compared with the inhibitory effect of each compound alone. Thus, further elucidation of the in vitro antiviral mechanism of CSE shown in this study will lead to the development of CSE-like molecules for the entry inhibition of HTLV-1.
authors.affiliation: Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Jinno-Oue
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tanaka
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Shimizu
authors.forename: Takahisa
authors.initials: T
authors.lastname: Mori
authors.forename: Nobuo
authors.initials: N
authors.lastname: Sugiura
authors.forename: Koji
authors.initials: K
authors.lastname: Kimata
authors.forename: Hiroki
authors.initials: H
authors.lastname: Isomura
authors.forename: Hiroo
authors.initials: H
authors.lastname: Hoshino
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism*; D002460:Cell Line; D002809:Chondroitin Sulfates / Q000302:isolation & purification / Q000378:metabolism*; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D049832:Decapodiformes / Q000737:chemistry; D015368:Human T-lymphotropic virus 1 / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D011485:Protein Binding; D013601:T-Lymphocytes / Q000821:virology; D014759:Viral Envelope Proteins / Q000378:metabolism; D053585:Virus Attachment / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D014759:Viral Envelope Proteins; D002809:Chondroitin Sulfates